SUMMARY
γ-secretase inhibitors (GSIs) have been recently proposed as chemopreventive agents in gastrointestinal neoplasia, because they lead, through inhibition of the Notch signaling pathway, to goblet cell conversion in some intestinal adenomas of the ApcMin mice, and halt epithelial cell proliferation. In this study, we examine in depth, in normal mice, the effects of a GSI, dibenzazepine (DBZ), intraperitoneally administered for 8 days at a non toxic dose, on the gene expression pattern of secretory mucin (MUC), goblet cell conversion, organization of the crypt structural-proliferative units, stem cell niche and apoptotic compartments, along the entire length of the small intestine and colon. We demonstrate that DBZ elicits a homogeneous goblet cell conversion all along the mouse intestinal tract, associated with an overexpression of the gene Muc2 without ectopic expression of the gastric genes Muc5ac and Muc6, and with the emergence of lysozyme-positive ‘intermediate cells’ in the colon. Furthermore, DBZ treatment induces a heterogeneous reorganization of the crypt structural-proliferative units along the intestinal tract and of the stem cell niche in the colon, without disturbing the apoptotic compartment. These findings point to uncoupled effects of a GSI on goblet cell conversion and reorganization of the intestinal crypt structural-proliferative units and stem cell niche, and suggest caution in the use of GSIs as chemopreventive agents for intestinal neoplasia.
- Received January 6, 2011.
- Accepted July 28, 2011.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms
Article navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
First person – a new series of interviews
We are pleased to announce a new series of interviews with the first authors of articles published in DMM, giving authors the opportunity to promote themselves alongside their papers and share their thoughts on being an early career researcher. We launch the series with two interviews; the first is with Josefin Fernius, first author on a Research article investigating the subcellular effects of human neurodegenerative disease proteins using Drosophila leg neurons. The second is with Aaro Salminen and Lillian Garrett, co-first authors on a Research article revealing how Meis1 affects motor phenotypes and the sensorimotor system in mice.
Editor’s choice – Loss of the Wnt receptor frizzled 7 in the mouse gastric epithelium
Elizabeth Vincan and colleagues reveal in this Editor’s choice Research article that Wnt signalling regulates homeostasis of the gastric epithelium via the Fzd7 receptor, which could be a target for therapeutic intervention in gastric cancer.
Call for papers: Cancer metabolism special collection
DMM invites you to submit original research for a special collection focused on the dysregulation of metabolic pathways in cancer initiation, progression and resistance to treatment. This ongoing collection will be launched with a special issue scheduled for publication in spring 2018, with the special issue guest edited by Almut Schulze (University of Würzberg, Germany) and Mariia Yuneva (Crick Institute, London, UK).
Find out more here.
Travelling Fellowship - a lifestyle of collaboration
A Travelling Fellowship from DMM allowed David Houghton from the Institute of Neuroscience at Newcastle University to travel to ICAN in Paris, where he refined his techniques for DNA extraction, processing and sequencing. The most crucial part of David’s visit, however, was the number of collaborations he was able to establish for future projects researching the impact of diet and lifestyle on gut microbiota in mitochondrial and metabolic disease. Read his story here.
Where could your research take you? The deadline for the current round of applications for a DMM Travelling Fellowship is 31 August. Find out more here.